Xiamen University

Xiamen Innovax Biotech Co., Ltd.

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Yang Sheng Tang Company Limited

Rutgers, the State University of New Jersey

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Beijing University of Chemical Tehcnology

Xiamen Innodx Biotech Co., Ltd.

University of Medicine and Dentistry of New Jersey

Academy of Military Medical Sciences

Ningshao Xia

Jun Zhang

Song Li

Wu Zhong

Shaowei Li

Ying Gu

Shengxiang Ge

Wenxin Luo

Quan Yuan

Yixin Chen

Huirong Pan

Xiangzhong Ye

Tong Cheng

Minxi Wei

Tianying Zhang

Chunyan Yang

Zhiqiang He

Jin Wang

Daning Wang

Tingdong Li

Hua Zhu

Xinlin Liu

Feihai Xu

Zhihai Li

Maozhou He

Shuo Song

Qinjian Zhao

Yimin Li

Cuiling Song

Ji Miao

Xianglin Kong

Chenguang Shen

Wei Wang

Bo Liu

Yijian Li

Yuanjun Zeng

Guosong Wang

Mengya Zhang

Barney S Graham

Jason Scott McLellan

Man Chen

Xi Huang

Ying Zhang

Ruiyuan Cao

Honglin Chen

Junyu Chen

Jie Chen

Junkai Wan

Xueran Guo

Jinjie Li

Lianzhi Jia

Shiyin Zhang

Yike Li

Yingbin Wang

Xiaofen Huang

Siyi Chen

Miaoge Xue

Min Zhao

Pengfei Gao

Rui Li

Limin Zhang

Bing Zhou

Zuxing Weng

Liuwei Song

Yongliang Yang

Shaojun Ke

Xiaobing Mo

Yangling Xian

Wentong Shen

Zhongyi Li

Minghui Xie

Tao Zhang

Yali Zhang

Yi Guan

Zhiping Wang

Yurou Yang

Yong Luo

Juan Zhang

Chenghao Huang

Longfa Xu

Jingjie Shi

Wenkun Fu

Yangtao Wu

Lina Lin

Jixian Tang

Can Wen

Jiali Cao

Xiaozhen Kang

Wenbin Zhou

Xinchu Xiang

Meifeng Nie

Xianbo Qiu

Qingshun Guo

Zizheng Zheng

Liangmin Huang

Shangzhi Ji

Zixin Qiu

Disclosed is a zinc zoledronate micro-nanoparticle adjuvant, which contains zinc and zoledronic acid and optionally contains a phosphate and aluminum. The preparation method therefor comprises performing mixed precipitation on a soluble salt solution containing zinc ions, zoledronic acid, and sodium hydroxide. The adjuvant can be used to prepare vaccines, etc.

Preparation of zinc zoledronate micro-nanoparticle adjuvant and use thereof as vaccine adjuvant

The present invention pertains to the field of pharmaceutical technology. Specifically, the present invention relates to a zinc risedronate micro/nano adjuvant with sustained-release function formed by mineralization of zinc ions and risedronic acid as main components and its use as a vaccine adjuvant. The present invention also relates to a method for preparing zinc risedronate micro/nano adjuvant. The present invention also relates to a chemical composition, vaccine adjuvant and vaccine composition comprising zinc risedronate micro/nano adjuvant. The present invention also relates to a use of zinc risedronate micro/nano adjuvant as a vaccine adjuvant.

Preparation of zinc risedronate micro/nano adjuvant and use thereof as vaccine adjuvant

Disclosed are antibodies to anti-hepatitis B surface antigen (HBsAg) (especially humanized antibodies), nucleic acid molecules encoding same, methods for preparing same, and pharmaceutical compositions containing same. The antibodies have higher affinity for HBsAg at neutral pH than at acidic pH, thereby significantly enhancing the virus clearance efficiency and prolonging the virus inhibition time. The antibodies and the pharmaceutical compositions can be used for preventing and/or treating HBV infections or diseases related to HBV infections (e.g., hepatitis B), for neutralizing the virulence of HBV in a subject (e.g., a human), for reducing the serum level of HBV DNA and/or HBsAg in the body of the subject, or for activating the humoral immune response of the subject (e.g., a chronic HBV infected or chronic hepatitis B patient) against HBV.

Anti-hepatitis B virus antibody and uses thereof

A pseudorabies virus (PRV) or a modified form thereof, or a genome sequence or a cDNA sequence containing the PRV or the modified form thereof, or nucleic acid molecules of a complementary sequence of the cDNA sequence, for treating tumors of subjects and/or reducing or inhibiting tumor recurrence, and for preparation of a pharmaceutical composition used for treating the tumors of the subjects and/or reducing or inhibiting the tumor recurrence. A method for treating tumors and/or reducing or inhibiting tumor recurrence, comprising a step of administering, on a subject having a need, the PRV or the modified form thereof, or nucleic acid molecules of the genome sequence containing the PRV or the modified form thereof.

Pseudorabies virus for treating tumors

Provided are a mutated HPV51 L1 protein or a variant thereof, a coding sequence thereof, a preparation method therefor, and a virus-like particle containing same, wherein the protein or the variant and the virus-like particle thereof are capable of inducing neutralizing antibodies against at least two types of HPV (for example, HPV51 and HPV69, or HPV51, HPV69 and HPV26). Also provided is the use of the above-mentioned protein and the virus-like particle for preparing a pharmaceutical composition or a vaccine, wherein the pharmaceutical composition or the vaccine can be used to prevent infections of the at least two types of HPV and diseases caused by the infections, such as cervical cancer and condyloma acuminatum.

Human papilloma virus type 51 L1 protein mutants

Provided are an enterovirus D68 (EV-D68) or a modified form thereof, or a nucleic acid molecule comprising a genomic sequence or cDNA sequence of the EV-D68 or a modified form thereof, or a complementary sequence of the genomic sequence or cDNA sequence, or a pharmaceutical composition comprising the EV-D68 or a modified form thereof, or the nucleic acid molecule, and use of the EV-D68 or a modified form thereof, or the nucleic acid molecule in the manufacture of a pharmaceutical composition for treating a tumor.

Virus for treatment of tumor

The present invention relates to a mutated HPV18 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (for example, HPV18 and HPV45, or HPV18, HPV45 and HPV59), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.

Mutant of L1 protein of human papillomavirus type 18

Provided are use of an Echovirus 25 (ECHO25) or a modified form thereof, or a nucleic acid molecule comprising a genomic sequence or cDNA sequence of the ECHO25 or a modified form thereof, or a complementary sequence of the genomic sequence or cDNA sequence, in treatment of a tumor in a subject, and in the manufacture of a medicament for treatment a tumor in a subject.

Echovirus for treatment of tumors

The invention relates to the field of virology and tumor therapy. In particular, the present invention provides a recombinant herpes simplex virus (HSV) capable of specifically replicating at a high level in a tumor cell and effectively killing the tumor cell, but replicating at low levels in normal cells, thereby the recombinant herpes simplex virus of the present invention not only has high lethality against tumor cells, but also has significantly decreased side effects (especially neurotoxicity). Further, the present invention relates to a viral vector constructed based on the recombinant herpes simplex virus, a pharmaceutical composition comprising the recombinant herpes simplex virus or the viral vector, and the use of the recombinant herpes simplex virus or the viral vector. The recombinant herpes simplex virus of the present invention can be used to infect and kill tumor cells, and can be used for gene drug delivery into tumor cells for gene therapy.

Recombinant herpes simplex virus and use thereof

The invention relates to a mutated HPV66 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV66 and HPV56, or HPV66, HPV56 and HPV53), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.

Mutant of L1 protein of human papillomavirus type 66

The invention relates to a mutated HPV39 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV39 and HPV68, or HPV39, HPV68 and HPV70), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.

Mutant of L1 protein of human papillomavirus type 39

The disclosure relates to a mutant of hemagglutinin protein of H3N2 subtype influenza virus and use thereof. In addition, the disclosure also relates to a pharmaceutical composition (e.g., a vaccine) comprising the mutant, a method for preparing the mutant, and a method of using the mutant for prevention and/or treatment of an infection of influenza virus and/or a disease (e.g., an influenza) caused by the infection.

Mutant of hemagglutinin protein of H3N2 subtype influenza virus and use thereof

The invention relates to a truncated rotavirus VP4 protein, a sequence encoding the same, a method for preparing the same, and a pharmaceutical composition and a vaccine comprising the protein, wherein the protein, the pharmaceutical composition and the vaccine are useful for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea. The invention further relates to use of the protein in the manufacture of a pharmaceutical composition or a vaccine for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea.

Truncated rotavirus VP4 protein and application thereof

Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.

ORF7 deficient varicella virus, vaccine comprising the virus and use thereof

Provided are a mutated HPV16 L1 protein (or a variant thereof), a sequence encoding the same and a method for preparing the same, as well as a virus-like particle comprising the same. The protein (or variant thereof) and the virus-like particle are capable of inducing neutralizing antibodies against at least two types of HPV (e.g., HPV16 and HPV35, or HPV16, HPV35, and HPV31), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. Also provided are a use of the above protein and virus-like particle in the manufacture of a pharmaceutical composition or vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.

Mutant of L1 protein of human papillomavirus type 16

Growing community of inventors

Xiamen, China

Ningshao Xia